Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Type II Diabetes II: Pathophysiology

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.

Gastritis-II: Pathophysiology

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...

Autoimmune Disorders

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Euthyroidism and Long-Term Remission of Graves' Hyperthyroidism Following Treatment With an FcRn Blocker: A Case Report.

Thyroid : official journal of the American Thyroid Association·2026

Same author

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.

The Journal of clinical endocrinology and metabolism·2025

Same author

Type 1 Diabetes and Other Autoimmune Diseases-Epidemiology, Pathophysiology and Screening.

Endocrinology, diabetes & metabolism·2025

Same author

Comparison of the 2021 EUGOGO guidelines and the 2022 ATA/ETA consensus statement for the management of Graves' orbitopathy.

European thyroid journal·2025

Same author

Graves' disease in ectopic thyroid tissue: a scoping review and a case study.

European thyroid journal·2025

Same author

Unravelling the pathogenic mechanisms in Graves' orbitopathy.

European thyroid journal·2025

Search research articles

Related Experiment Video

Updated: May 16, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

Polyglandular autoimmune syndrome type II.

George J Kahaly¹

¹Gutenberg University Medical Center, Department of Medicine I, 55101 Mainz, Germany. gkahaly@uni-mainz.de

Presse Medicale (Paris, France : 1983)

|November 20, 2012

Summary

Polyglandular autoimmune syndromes (PAS) involve multiple autoimmune disorders. Genetic susceptibility, particularly involving human leucocyte antigen (HLA) genes, is key, but environmental factors also play a role in developing these conditions.

Area of Science:

Immunology
Genetics
Endocrinology

Background:

Polyglandular autoimmune syndromes (PAS) are a group of autoimmune disorders affecting multiple endocrine glands.
PAS is classified into juvenile (PAS I) and adult (PAS II) types.
Key features include lymphocyte infiltration, organ-specific autoantibodies, immune defects, and associations with human leucocyte antigen (HLA) genes.

Purpose of the Study:

To explore the genetic and immunological underpinnings of polyglandular autoimmune syndromes.
To understand the diagnostic and prognostic value of autoantibodies in PAS.
To identify genetic susceptibility factors for PAS I and PAS II.

Main Methods:

Review of existing literature on the pathophysiology of PAS.
Analysis of genetic associations, including HLA, CTLA-4, and PTPN22 genes.

More Related Videos

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Related Experiment Videos

Last Updated: May 16, 2026

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis

Published on: December 15, 2011

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Published on: May 29, 2020

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Accelerated Type 1 Diabetes Induction in Mice by Adoptive Transfer of Diabetogenic CD4+ T Cells

Published on: May 6, 2013

Discussion of autoantibody detection for diagnosis and risk assessment.

Main Results:

Autoantibodies serve as diagnostic markers and can identify at-risk individuals.
Genetic susceptibility, primarily linked to HLA genes, is necessary but not sufficient for disease development.
Specific genes like HLA, CTLA-4, and PTPN22 are associated with increased risk for PAS II.

Conclusions:

Understanding genetic defects and environmental triggers is crucial for developing targeted therapies for organ-specific autoimmunity.
Immunotherapeutic approaches successful in one autoimmune disorder may benefit related conditions.
Further research into the interplay of genetics and environment is needed for effective treatment strategies.